FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008405909> ?p ?o ?g. }

• W2008405909 abstract "Background The Alzheimer's Disease Assessment Scale‐Cognitive (ADAS‐Cog) has been used widely as a cognitive end point in Alzheimer's Disease (AD) clinical trials. Efforts to treat AD pathology at earlier stages have also used ADAS‐Cog, but failure in these trials can be difficult to interpret because the scale has well‐known ceiling effects that limit its use in mild cognitive impairment (MCI) and early AD. A wealth of data exists in ADAS‐Cog from both historical trials and contemporary longitudinal natural history studies that can provide insights about parts of the scale that may be better suited for MCI and early AD trials. Methods Using Alzheimer's Disease Neuroimaging Initiative study data, we identified the most informative cognitive measures from the ADAS‐Cog and other available scales. We used cross‐sectional analyses to characterize trajectories of ADAS‐Cog and its individual subscales, as well as other cognitive, functional, or global measures across disease stages. Informative measures were identified based on standardized mean of 2‐year change from baseline and were combined into novel composite endpoints. We assessed performance of the novel endpoints based on sample size requirements for a 2‐year clinical trial. A bootstrap validation procedure was also undertaken to assess the reproducibility of the standardized mean changes of the selected measures and the corresponding composites. Results All proposed novel endpoints have improved standardized mean changes and thus improved statistical power compared with the ADAS‐Cog 11. Further improvements were achieved by using cognitive–functional composites. Combining the novel composites with an enrichment strategy based on cerebral spinal fluid beta‐amyloid (Aβ 1‐42 ) in a 2‐year trial yielded gains in power of 20% to 40% over ADAS‐Cog 11, regardless of the novel measure considered. Conclusion An empirical, data‐driven approach with e xisting instruments was used to derive novel composite scales based on ADAS‐Cog 11 with improved performance characteristics for MCI and early AD clinical trials. Together with patient enrichment based on Aβ 1‐42 pathology, these modified endpoints may allow more efficient clinical trials in these populations and can be assessed without modifying current test administration procedures in ongoing trials." @default.
• W2008405909 created "2016-06-24" @default.
• W2008405909 creator A5003330833 @default.
• W2008405909 creator A5014646926 @default.
• W2008405909 creator A5026214791 @default.
• W2008405909 creator A5036259423 @default.
• W2008405909 creator A5068486256 @default.
• W2008405909 creator A5088427003 @default.
• W2008405909 creator A5089486050 @default.
• W2008405909 creator A5021135425 @default.
• W2008405909 date "2012-11-05" @default.
• W2008405909 modified "2023-10-01" @default.
• W2008405909 title "The ADAS‐Cog revisited: Novel composite scales based on ADAS‐Cog to improve efficiency in MCI and early AD trials" @default.
• W2008405909 cites W113797418 @default.
• W2008405909 cites W1598503899 @default.
• W2008405909 cites W1895538680 @default.
• W2008405909 cites W1953027527 @default.
• W2008405909 cites W1969313677 @default.
• W2008405909 cites W1983349802 @default.
• W2008405909 cites W2003919893 @default.
• W2008405909 cites W2007164886 @default.
• W2008405909 cites W2008301592 @default.
• W2008405909 cites W2013078308 @default.
• W2008405909 cites W2018139165 @default.
• W2008405909 cites W2024719735 @default.
• W2008405909 cites W2030726478 @default.
• W2008405909 cites W2033252867 @default.
• W2008405909 cites W2037099926 @default.
• W2008405909 cites W2083282996 @default.
• W2008405909 cites W2086572083 @default.
• W2008405909 cites W2094384124 @default.
• W2008405909 cites W2107820540 @default.
• W2008405909 cites W2112436745 @default.
• W2008405909 cites W2115095363 @default.
• W2008405909 cites W2118753807 @default.
• W2008405909 cites W2148744914 @default.
• W2008405909 cites W2157064933 @default.
• W2008405909 cites W2159887611 @default.
• W2008405909 cites W2166770399 @default.
• W2008405909 cites W2169373315 @default.
• W2008405909 cites W4249663519 @default.
• W2008405909 cites W4366067834 @default.
• W2008405909 doi "https://doi.org/10.1016/j.jalz.2012.05.2187" @default.
• W2008405909 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3732822" @default.
• W2008405909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23127469" @default.
• W2008405909 hasPublicationYear "2012" @default.
• W2008405909 type Work @default.
• W2008405909 sameAs 2008405909 @default.
• W2008405909 citedByCount "64" @default.
• W2008405909 countsByYear W20084059092013 @default.
• W2008405909 countsByYear W20084059092014 @default.
• W2008405909 countsByYear W20084059092015 @default.
• W2008405909 countsByYear W20084059092016 @default.
• W2008405909 countsByYear W20084059092017 @default.
• W2008405909 countsByYear W20084059092018 @default.
• W2008405909 countsByYear W20084059092019 @default.
• W2008405909 countsByYear W20084059092020 @default.
• W2008405909 countsByYear W20084059092021 @default.
• W2008405909 countsByYear W20084059092022 @default.
• W2008405909 countsByYear W20084059092023 @default.
• W2008405909 crossrefType "journal-article" @default.
• W2008405909 hasAuthorship W2008405909A5003330833 @default.
• W2008405909 hasAuthorship W2008405909A5014646926 @default.
• W2008405909 hasAuthorship W2008405909A5021135425 @default.
• W2008405909 hasAuthorship W2008405909A5026214791 @default.
• W2008405909 hasAuthorship W2008405909A5036259423 @default.
• W2008405909 hasAuthorship W2008405909A5068486256 @default.
• W2008405909 hasAuthorship W2008405909A5088427003 @default.
• W2008405909 hasAuthorship W2008405909A5089486050 @default.
• W2008405909 hasBestOaLocation W20084059092 @default.
• W2008405909 hasConcept C118552586 @default.
• W2008405909 hasConcept C126322002 @default.
• W2008405909 hasConcept C154945302 @default.
• W2008405909 hasConcept C169900460 @default.
• W2008405909 hasConcept C203092338 @default.
• W2008405909 hasConcept C41008148 @default.
• W2008405909 hasConcept C4661277 @default.
• W2008405909 hasConcept C535046627 @default.
• W2008405909 hasConcept C58693492 @default.
• W2008405909 hasConcept C6057870 @default.
• W2008405909 hasConcept C71924100 @default.
• W2008405909 hasConceptScore W2008405909C118552586 @default.
• W2008405909 hasConceptScore W2008405909C126322002 @default.
• W2008405909 hasConceptScore W2008405909C154945302 @default.
• W2008405909 hasConceptScore W2008405909C169900460 @default.
• W2008405909 hasConceptScore W2008405909C203092338 @default.
• W2008405909 hasConceptScore W2008405909C41008148 @default.
• W2008405909 hasConceptScore W2008405909C4661277 @default.
• W2008405909 hasConceptScore W2008405909C535046627 @default.
• W2008405909 hasConceptScore W2008405909C58693492 @default.
• W2008405909 hasConceptScore W2008405909C6057870 @default.
• W2008405909 hasConceptScore W2008405909C71924100 @default.
• W2008405909 hasFunder F4320306305 @default.
• W2008405909 hasFunder F4320332161 @default.
• W2008405909 hasFunder F4320337337 @default.
• W2008405909 hasFunder F4320337363 @default.
• W2008405909 hasIssue "1S" @default.
• W2008405909 hasLocation W20084059091 @default.
• W2008405909 hasLocation W20084059092 @default.
• W2008405909 hasLocation W20084059093 @default.

• next